Nanna Therapeutics
Gonçalo C. Pereira is a skilled scientist with extensive experience in mitochondrial biology and toxicology. Currently serving as a Scientist I at Astellas Engineered Small Molecules U.K. Ltd. since November 2022, Gonçalo previously held positions as Senior Project Scientist at MRC Mitochondrial Biology Unit and Research Associate at both the University of Bristol and UCL. Notably, Gonçalo contributed to the development of a novel biochemical assay during a Wellcome Trust project in Prof. Ian Collinson's lab and characterized mitochondrial morphology in ischemic injury under Prof. Andrew Halestrap's supervision. Further academic background includes a PhD in Biosciences - Toxicology and a degree in Biochemistry from Universidade de Coimbra, as well as research training focused on doxorubicin cardiotoxicity and the effects of berberine.
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer.Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treatage-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies.Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.